Research
A long-term follow-up study investigating health-related quality of life and resource use in survivors of severe sepsis: comparison of recombinant human activated protein C with standard care
-
* Corresponding author: Christopher J Longo cjlongo@mcmaster.ca
1 McMaster University, Main Street West, Hamilton, Ontario, Canada, L8S 4M4
2 Kingston General Hospital, Queen's University, Stuart Street, Kingston, Ontario, Canada, K7L 2V7
3 Eli Lilly Canada Inc., Danforth Avenue, Scarborough, Ontario, Canada, M1N 2E8
4 Sunnybrook Health Sciences Centre, Bayview Avenue, Toronto, Ontario, Canada, M4N 3M5
5 London Health Sciences Centre, Commissioners Road East, London, Ontario, Canada, N6A 5W9
6 Clinical Research Centre, Kingston General Hospital, Stuart Street, Kingston, Ontario, Canada, K7L 2V7
Critical Care 2007, 11:R128 doi:10.1186/cc6195
See related commentary by Erickson and Martin., http://ccforum.com/content/12/1/109
Published: 11 December 2007Additional files
Additional file 1:
A Word document outlining the study criteria used to define the presence of severe sepsis.
Format: DOC Size: 43KB Download file
This file can be viewed with: Microsoft Word Viewer
